U.S. markets closed
  • S&P 500

    4,473.75
    -6.95 (-0.16%)
     
  • Dow 30

    34,751.32
    -63.07 (-0.18%)
     
  • Nasdaq

    15,181.92
    +20.39 (+0.13%)
     
  • Russell 2000

    2,232.91
    -1.54 (-0.07%)
     
  • Crude Oil

    72.57
    -0.04 (-0.06%)
     
  • Gold

    1,753.80
    -41.00 (-2.28%)
     
  • Silver

    22.89
    -0.91 (-3.83%)
     
  • EUR/USD

    1.1772
    -0.0054 (-0.46%)
     
  • 10-Yr Bond

    1.3310
    +0.0270 (+2.07%)
     
  • GBP/USD

    1.3786
    -0.0049 (-0.36%)
     
  • USD/JPY

    109.7300
    +0.3700 (+0.34%)
     
  • BTC-USD

    47,343.34
    -705.14 (-1.47%)
     
  • CMC Crypto 200

    1,209.85
    -23.43 (-1.90%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Nikkei 225

    30,323.34
    -188.37 (-0.62%)
     

AbbVie Nabs Eye Disease Gene Therapy From Regenxbio for Up to $1.8 Billion

·2 min read
AbbVie Nabs Eye Disease Gene Therapy From Regenxbio for Up to $1.8 Billion
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

AbbVie will pay Regenxbio up to $1.8 billion for a share of the potential profits from sales of the company's experimental gene therapy to treat a variety of eye diseases.